Background: Hepatocellular carcinoma (HCC) is a worldwide health problem . It is considered the second most common cause of cancer-associated fatalities and it is the sixth major cause of cancer all over the world. This variance between occurrence and fatality ensures that it is an aggressive tumor with poor prognosis .
Aim and objectives : to evaluate the diagnostic value of serum-CD166 in patients with hepatocellular carcinoma (HCC).
Methods: This study was conducted on 90 subjects attending Department of Hepatology , Gastroenterology and Infectious Diseases in Benha University Hospitals as a cross sectional study. Subjects were classified into three groups; Human CD166 and alpha fetoprotein were assessed in all groups , all laboratory investigations were done .
Results: Serum CD166 concentrations were much higher in HCC than in cirrhosis and healthy individuals . A positive correlation was found between serum CD166 and AFP. The area under the receiver operating characteristic curve for serum-CD166 was 0.951, while in AFP (AUC-ROC, 0.943) , with a cut-off of 1357ng/ml (sensitivity: 94.3%, specificity: 97.1%) for CD!66 .
Conclusion: Serum CD166 is a novel diagnostic tumor marker for HCC.